A Phase 1/2 interventional study of Arfolitixorin and Leucovorin in Metastatic Colorectal Cancer (mCRC), sponsored by Isofol Medical AB. Recruiting at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Isofol Medical AB · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 353 studies in Colorectal Neoplasms with a site in Germany — 63 open to participants now, 90 under way, 19 of them phase 3. Colorectal Neoplasms · Germany.
Among the 353 studies in Colorectal Neoplasms with a site in Germany, this one is the 191st largest by planned enrollment of the 290 interventional ones that give a count, is one of 25 that started in 2025, is one of 39 in phase 1/2, reaches primary completion later than 65 of the 89 other live ones, and was the 331st registered.
6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →63 of the 353 studies in Colorectal Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
AbbVie · Sites in Germany, United States, Belgium and 7 more countries
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in Germany, United States, Argentina and 16 more countries
Ages 18+
University of Regensburg · Sites in Germany
Ages 18+ · Healthy volunteers
Incyte Corporation · Sites in Germany, United States, Argentina and 19 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 22 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
353 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 91 · Phase 2 129 · Phase 3 78 · Phase 4 5
First in 1991; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 76 across 4,809 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 169 across the 290 interventional studies, 542 across the 57 observational. Of the 228 that completed or were terminated, 79 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
219 of 353 have an industry lead sponsor. The 10 most frequent:
Isofol Medical AB is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Isofol Medical AB has 4 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
26 of the studies in Colorectal Neoplasms with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05008809Phase 3Dominik Paul ModestPost-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) | 2027-11 |
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT05991102Charite University, Berlin, GermanyAmplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer | 2026-11 |
| NCT06607458Delcath Systems Inc.Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | 2026-12 |
| NCT01789229Medical University of ViennaEstablishment of a Tumor Bank for Tissue Samples | 2026-12 |
Add all 26 to your calendar (.ics) → With an account.
Among the 353 studies in Colorectal Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 90 people will participate in the study.
There is already a standard therapy for treatment of colorectal cancer. This therapy contains a combination of the medicines leucovorin, fluorouracil, oxaliplatin/irinotecan and bevacizumab/cetuximab/panitumumab.
The sponsoring company is developing the new therapy called arfolitixorin. In this study, patients with colorectal cancer will be given arfolitixorin instead of the standard treatment leucovorin. Different patients will receive treatment with different strengths (doses) of arfolitixorin. Treatment with fluorouracil, oxaliplatin/irinotecan and bevacizumab/cetuximab/panitumumab will also be administrated.
The researchers want to find out if arfolitixorin could have an advantage over the standard therapy with leucovorin. They also want to investigate which dose of arfolitixorin is the maximum tolerated dose and if arfolitixorin is safe to use.
The product being tested, arfolitixorin, like leucovorin, belongs to a group of substances called folates which are naturally occurring forms of a type of B vitamin. Folates are administered in combination with one or more chemotherapeutic agents to enhance their effect on cancer cells.
The main mechanism of action of arfolitixorin is the same as that of leucovorin when used together with fluorouracil. However, leucovorin must first be converted into the active form in the body, whereas arfolitixorin already is in the active form. Leucovorin does not work equally well in all patients. By bypassing the metabolic activation of arfolitixorin, it is assumed that arfolitixorin works in a larger number of patients and has a stronger and longer efficacy in cancer treatment together with fluorouracil.
However, the efficacy of arfolitixorin has not yet been proven, and the substance has not been approved for the treatment of colorectal cancer. To date, arfolitixorin has been tested by around 420 volunteers and patients with colorectal cancer in different clinical studies. These studies have shown that arfolitixorin is safe and potentially can be of clinical benefit in patients with colorectal cancer when used in combination with fluorouracil, oxaliplatin and bevacizumab.
In the largest clinical study completed so far, arfolitixorin was shown to be equally effective compared to standard therapy with leucovorin, but not more effective. Additional results from this study suggested that the dose of arfolitixorin given did not deliver a sufficiently high amount of active substance into the tumor. Therefore, higher doses of arfolitixorin will be tested in this study to possibly achieve a better clinical effect. Further analyses also indicated that high accuracy regarding the timing and duration of the administration of the different treatments is important to achieve better efficacy of arfolitixorin.
Based on the available data, and the risk and benefit assessments performed, the Sponsor deems that it is relevant to further investigate the safety and tolerability, as well as the efficacy of arfolitixorin when given in combination with fluorouracil, oxaliplatin/irinotecan and bevacizumab/cetuximab/panitumumab. The proposed study design is believed to address all the main previous findings with the purpose to increase the efficacy while maintaining an acceptable safety profile.
The study is divided into two parts. In the first part, up to five different doses of arfolitixorin will be investigated to find the maximum tolerated dose of arfolitixorin as well as the optimal duration time of administration.
The second part of the study will be based on the results from the first part. Two doses of arfolitixorin will be tested for safety, tolerability and anti-tumor effect. In the second part, participants will be randomly assigned to one of two dose groups or a control group (receiving the Standard of Care) using a computer program. This so-called randomization procedure is comparable to tossing a coin.
All patients that participate in the study will receive treatment every 2 weeks. The treatment will be given as an infusion into a vein. The number of treatment administrations that will be given is not predetermined but depends on the progression of the patient's disease.The treatment will continue every 2 weeks as long as the patient benefits from the treatment.
During the study period, the patient's disease and potential response to treatment, including shrinkage of the tumor and/or improvement of symptoms, will be monitored by imaging examinations, using so-called computer tomography (CT) or magnetic resonance imaging (MRI). The patient's state of health will also be monitored by physical examinations, and laboratory tests of urine and blood, as well as assessment of any side effects.
This is a Phase 1b/2 study to determine the safety and preliminary efficacy of arfolitixorin (replacing LV) as part of eligible 5-FU based backbone treatment regimens in patients with mCRC eligible for first-line therapy.
The study will include a Phase 1b dose-finding part followed by a randomized Phase 2 dose optimization part including an SoC arm.
Eligible patients will undergo baseline assessments (within 28 days prior to treatment initiation) and repeat imaging using computed tomography (CT) or magnetic resonance imaging (MRI) after 6 and 12 weeks, and every 12 weeks thereafter as long as on study treatment.
In Phase1b, patients will receive treatment with ARFOX + bevacizumab. In Phase 2, patients will receive treatment with arfolitixorin (replacing LV) as part of eligible 5-FU based backbone treatment (i.e., ARFOX + bevacizumab/cetuximab/panitumumab or ARFIRI + bevacizumab/cetuximab/panitumumab) or SoC (including LV) as part of eligible 5-FU based backbone treatment (i.e., FOLFOX + bevacizumab/cetuximab/panitumumab or FOLFIRI + bevacizumab/cetuximab/panitumumab).
All patients will receive treatment every 14 days (+7 days) until progressive disease (PD), or clear clinical deterioration according to the Investigator's judgment, and as long as the patient is tolerating the treatment and agrees to continue.
After completion of study treatment, patients will complete an EOT visit within 30 days of discontinuation, and all patients should be followed in line with the site's SoC scheme.
Subsequent study follow-up contacts/visits will be performed every 90 days (±15 days) after the EOT visit treatment, until 60% of the OS events have been collected or 24 months after last patient in (LPI), whichever comes first. The follow-up contacts may be conducted via telephone, via clinic visits, via local practitioner, via review of medical records or other means found suitable.
At the follow-up visits, information on any subsequent cancer treatments will be collected, recording and assessment of serious adverse events (SAEs) considered to be related to the study treatment will be performed, and survival status will be noted. All AEs collected during the reporting period still ongoing at the EOT visit will be followed until resolution or stabilization, or until deemed not necessary by the Investigator. All SAEs collected during the reporting period still ongoing at the EOT visit will be followed up until the patient has recovered, stabilized, or recovered with sequelae.
During the Phase 1b part of the study, a dose escalation design will be utilized to identify the MTD and the duration of administration of arfolitixorin to be used in combination with 5-FU, oxaliplatin and bevacizumab. A Safety Review Committee (SRC) will review AEs, SAEs, dose-limiting toxicities (DLTs) as defined in the Clinical Study Protocol, and PK data and make recommendations regarding which dose level and cohort size to be tested for the next cohort, as well as the MTD. The SRC may also make recommendations of the duration of the infusion if there are safety findings that potentially correlate to a non-acceptable maximum plasma (peak) drug concentration (Cmax).
The dose escalation schema will be based on a Bayesian optimal interval (BOIN) design where the decision of dose escalation or de-escalation involves a simple comparison of the observed DLT rate at the current dose with the prespecified dose escalation and de-escalation boundaries.
The Phase 2 part of the study will be a randomized study where patients will be allocated to 1 of 2 dose levels of arfolitixorin, or to treatment with SoC. The higher dose level of arfolitixorin will be the MTD as determined in Phase 1b, and the lower dose will be a dose level below the MTD in Phase 1b, as determined by the SRC. The SRC will also review safety and efficacy data on a regular basis during Phase 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase 2:
Histologically confirmed, colorectal adenocarcinoma with metastatic disease, eligible for first-line therapy with 5-FU based backbones, i.e.:
Patients with WT RAS or WT BRAF and left-sided tumors who are candidates for therapy with FOLFOX or FOLFIRI plus cetuximab or panitumumab.
a) ≥90 g/L. b) (ANC) ≥1.5 × 109/L. c) ≥100 × 109/L.
Adequate organ function as defined by the following laboratory values:
Exclusion Criteria:
Current evidence of any condition that could lead to higher risk or otherwise make participating in this study not in the best interest of the patient, including, but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The higher dose level of arfolitixorin in Phase 2 will be the maximum tolerated dose as determined in Phase 1b. The arfolitixorin will be given as i.v. infusion. Patients in this study will receive the IMP arfolitixorin as part of eligible 5-FU based backbone treatment (i.e., ARFOX + bevacizumab/cetuximab/panitumumab or ARFIRI + bevacizumab/cetuximab/panitumumab). The duration of the infusion will be determined in Phase 1b.
Drug: Arfolitixorin
The lower dose level of arfolitixorin in Phase 2 will be a dose level below the maximum tolerated dose in Phase 1b, as determined by the SRC. The arfolitixorin will be given as i.v. infusion. Patients in this study will receive the IMP arfolitixorin as part of eligible 5-FU based backbone treatment (i.e., ARFOX + bevacizumab/cetuximab/panitumumab or ARFIRI + bevacizumab/cetuximab/panitumumab). The duration of the infusion will be determined in Phase 1b.
Drug: Arfolitixorin
Patients in the SoC group will receive treatment with leucovorin (LV) as part of eligible 5-FU based backbone treatment (i.e., FOLFOX + bevacizumab/cetuximab/panitumumab or FOLFIRI + bevacizumab/cetuximab/panitumumab). LV will be administered as a 400 mg/m2 (for leucovorin) i.v. infusion as per the standard of care procedure at the study site and the specific label. (Note that other doses may be applicable as per the label, if e.g. levoleucovorin is given).
Other: Leucovorin
Every 14 days during treatment phase, antibody treatment (bevacizumab 5 mg/kg or cetuximab 500 mg/m² or panitumumab 6 mg/kg) will be administered as an i.v. infusion, followed by oxaliplatin 85 mg/m² or irinotecan 180 mg/m² administered as an i.v. infusion, and arfolitixorin administred as an i.v. infusion, followed by 5-FU administered as a 400 mg/m² i.v. bolus + a 2400 mg/m² i.v. infusion.
Patients in the SoC group will receive treatment with leucovorin as part of eligible 5-FU based backbone treatment. Every 14 days during treatment phase, antibody treatment (bevacizumab 5 mg/kg or cetuximab 500 mg/m² or panitumumab 6 mg/kg) will be administered as an i.v. infusion, followed by oxaliplatin 85 mg/m² or irinotecan 180 mg/m² administered as an i.v. infusion, and leucovorin 400 mg/m2 administered as an i.v. infusion, followed by 5-FU administered as a 400 mg/m² i.v. bolus + a 2400 mg/m² i.v. infusion.
Phase 1b: Number and severity of AEs and clinically significant abnormal laboratory findings
Number and severity of AEs and clinically significant abnormal laboratory findings, regardless of causal relationship to ARFOX + bevacizumab will be measured to evaluate the safety and tolerability of ARFOX + bevacizumab in patients with mCRC. The outcome of Phase 1b is to determine the MTD of arfolitixorin (ARFOX + bevacizumab).
Time frame: From enrollment until end of study, i.e. until death, an average of 24 months.
Phase 2: Number and severity of AEs, including clinically significant abnormal laboratory findings, after 2 pre-defined dose levels of arfolitixorin
Number and severity of AEs and clinically significant abnormal laboratory findings, regardless of causal relationship to any given treatment will be measured to evaluate the safety and tolerability of two pre-defined doses of arfolitixorin, in patients with mCRC, with SoC used as an internal control. The dose levels of arfolitixorin will be MTD and a dose level below MTD.
Time frame: From enrollment until end of study, i.e. until death, an average of 24 months.
Phase 2: Early signals of the anti-tumor activity of two pre-defined dose levels of arfolitixorin with SoC used as an internal control, in terms of ORR.
ORR will be determined by assessing early signals of the anti-tumor activity of two pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD). ORR is defined as the proportion of patients who have best overall response (BOR) of complete response (CR), or partial response (PR), measured from the start of the study treatment until the end of treatment (EOT) by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1).
Time frame: From enrollment until end of treatment, i.e. until progressive disease, or clear clinical deterioration according to the Investigator's judgment, and as long as the patient is tolerating the treatment and agrees to continue, an average of 11 months.
Phase 2: Early signals of the anti-tumor activity of two pre-defined dose levels of arfolitixorin with SoC used as an internal control, in terms of duration of response (DOR).
Duration of response (DOR) will be determined by assessing early signals of the anti-tumor activity of two pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD). DOR is defined as the duration of CR or PR.
Time frame: From enrollment until end of treatment, i.e. until progressive disease, or clear clinical deterioration according to the Investigator's judgment, and as long as the patient is tolerating the treatment and agrees to continue, an average of 11 months.
Phase 1b: Anti-tumor activity of ARFOX + bevacizumab in terms of ORR
Anti-tumor activity of ARFOX + bevacizumab will be assessed in patients with mCRC in terms of ORR, defined as the proportion of patients who have BOR of CR, or PR, measured by RECIST (version 1.1).
Time frame: From enrollment until end of treatment, i.e. until progressive disease, or clear clinical deterioration according to the Investigator's judgment, and as long as the patient is tolerating the treatment and agrees to continue, an average of 11 months.
Phase 1b: Anti-tumor activity of ARFOX + bevacizumab in terms of PFS.
Anti-tumor activity of ARFOX + bevacizumab will be assessed in patients with mCRC in terms of PFS, defined as the time from the first study dose date to the date of first documentation of disease progression or death (whichever occurs first).
Time frame: From the first study dose date to the date of first documentation of disease progression or death (whichever occurs first), an average 11 months.
Phase 1b: Anti-tumor activity of ARFOX + bevacizumab in terms of OS.
Anti-tumor activity of ARFOX + bevacizumab will be assessed in patients with mCRC in terms of OS, measured from the date of study treatment initiation to the date of death.
Time frame: From enrollment until end of study, i.e. until death, an average of 24 months.
Phase 1b: Plasma concentration of arfolitixorin
Plasma concentration of arfolitixorin will be measured to determine the PK profile of arfolitixorin, administered in combination with bevacizumab, oxaliplatin and 5-FU.
Time frame: Assessed just before the end of the infusion of arfolitixorin, and at 5, 10, 20, and 60 minutes after finished infusion of arfolitixorin, on day 1 and day 15.
Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of OS.
Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of OS. OS (efficacy endpoint), measured from the date of study treatment initiation to the date of death.
Time frame: From enrollment until end of study, i.e. until death, an average of 24 months.
Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of PFS.
Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of PFS, defined as the time from the date of the first study dose to the date of first documentation of disease progression or death (whichever occurs first).
Time frame: From the first study dose date to the date of first documentation of disease progression or death (whichever occurs first), an average 11 months.
Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of time to response (TTR).
Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of time to response (TTR). TTR, defined as the time from the first study dose date to the date of first documentation of CR or PR measured by RECIST (version 1.1).
Time frame: Measured from the start of the study treatment until the EOT visit, an average of 11 months.
Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of disease control rate (DCR).
Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of disease control rate (DCR). DCR, defined as the proportion of patients who have BOR of CR, PR, or SD ≥8 weeks.
Time frame: Measured from the start of the study treatment until the EOT visit, an average of 11 months.
Phase 2: Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin, in terms of depth of response (DpR).
Anti-tumor activity of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC will be assessed in terms of depth of response (DpR). DpR, defined as the maximum percentage change in tumor size compared with baseline.
Time frame: Measured from the start of the study treatment until the EOT visit, an average of 11 months.
Phase 2: OS as a safety outcome
OS will be assessed as a safety outcome for 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC.
Time frame: OS (safety [harm] endpoint), measured from the date of study treatment initiation to the date of death, 24 months.
Phase 2: Proportion of patients qualifying for curative metastasis resection after treatment with study drug
The effect of 2 pre-defined dose levels of arfolitixorin (MTD and a dose level below MTD) with SoC used as an internal control, in patients with mCRC, will be assessed by measuring the proportion of patients qualifying for curative metastasis resection.
Time frame: Measured from the start of the study treatment until the EOT visit, an average of 11 months.
Started Apr 2025 (actual). Primary completion is estimated for Nov 2028, 43 months after the start.
Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 43 months is below that.
Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: L-(+)-methylenetetrahydrofolic acid
Isofol Medical AB